Drugs / BAY 3401016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07211685 | Nov 2025 → Jul 2028 expected | Alport syndrome | Bayer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 3401016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07211685 ↗ |
| Action | Inhibit | “By blocking the action of the Sema3A protein, BAY 3401016 may prevent proteinuria and slow down the loss in kidney function due to AS.” NCT07211685 ↗ |
| Modality | Monoclonal antibody | “The study drug, BAY 3401016 (a monoclonal antibody)” NCT07211685 ↗ |